OncoLink Cancer Treatment and Resources
Link to OncoLink

Preliminary results of proton beam therapy for esophageal carcinoma

Reporter John P. Plastaras, MD, PhD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 13 de octubre del 2006

Presenter: Jiamin Li, Suwen Liu, Jianguang Zhang
Affiliation: Wanjie Proton Therapy Center, Zibo Wanjie Hospital, Boshan, Zibo, Shandong Province, China

Background

  • Esophageal cancer has historically been treated with a combination of surgery (when possible), photon radiotherapy, and chemotherapy
  • Radiation therapy doses to the esophagus are limited by nearby critical structures including the spinal cord, lungs, and heart, which can lead to acute and chronic toxicities.
  • Dose escalation in definitive radiation treatment of esophageal cancer is somewhat controversial, as the RTOG trial had excessive deaths on the high dose treatment arm (although several of these deaths were in patients that did not receive the full radiation dose). Currently used radiation doses are associated with poor local control.
  • Proton radiotherapy offers a way to increase the total tumor dose (and hopefully local control) without excessive toxicity for definitive radiation treatment of esophagus cancer
  • The feasibility of proton beam therapy for esophageal carcinoma was evaluated

Material and Methods

  • 4 patients with esophageal carcinoma (age 50-82) were treated at the Wanjie Proton Therapy Center between 12/2004 and 1/2006
  • Tumor length was determined by barium swallow, esophagoscopy, and PET-CT
  • Pathology: 3 SCC and 1 adenocarcinoma
  • Patients:
    • 1: middle third, 8 cm, regional mediastinal LN
    • 2: lower third, 5 cm, no regional LN
    • 3: upper third, 4 cm
    • 4: 82 yo with abdominal esophageal cancer, multiple gastric LN
    • 2 patients were treated with a combination of photons and protons, 2 were treated with protons only

Fields: 2 fields, AP-PA were used. 3-4 cm beyond primary tumor cephalad and caudad lateral borders were 1-1.5 cm
Fractionation/Dose: 1.8 or 2.0 Gy for photon and proton, total dose 60 to 66 Gy

Results

  • Some sample DVH curves were presented, with excellent coverage of target volumes with relatively low dose to lung and spinal cord. Comparison with conventional photon plans was not presented.
  • All patients completed treatment without interruption
  • No esophageal ulcers were seen with 12 month follow up
  • Radiation Esophagitis:
    • Grade 1 in 3 patients
    • Grade 2 in 1 patient
  • 3 of 4 had a complete response within 3 months
  • Patient 4 died of distant metastases 13 months later
  • Patient 3 relapsed 12 months later
  • Patients 1 and 2 are free of disease after >1 yr follow-up

Author's Conclusions

  • Proton beam radiation therapy was feasible, well-tolerated and effective for patient with esophageal cancer
  • Proton beam therapy can spare more surrounding tissues such as lung, heart, and spinal cord
  • Local control rates are comparable to those treated with conventional radiation therapy
  • Acute toxicity is lower that that for conventional therapy, but more follow-up is needed for late effects

Clinical and Scientific Implications

  • As proton therapy becomes more widespread, different malignancies will be treated with protons. Good dosimetry with AP-PA protons fields was demonstrated in this study, but a comparison with photon plans would have made this study more compelling.
  • 1 of 4 patients had a local relapse, but the dose was not specified for this patient
  • The use of concurrent chemotherapy was not specified in this study. The acute toxicities would likely be worse with concurrent chemotherapy.
  • Dose escalation for definitive radiotherapy of the esophagus may be attempted with proton therapy, given the ability to spare normal structures.
  • The use of proton therapy in the pre- or post-operative setting remains to be explored.

OncoLink I wish u knew...

Ms. Nibauer-Cohen talks about how yoga can help people with cancer cope with the stresses of the diagnosis. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS